[go: up one dir, main page]

HK1190094A1 - 用於治療前列腺癌的抗-α- 整聯蛋白抗體 - Google Patents

用於治療前列腺癌的抗-α- 整聯蛋白抗體

Info

Publication number
HK1190094A1
HK1190094A1 HK14103318.3A HK14103318A HK1190094A1 HK 1190094 A1 HK1190094 A1 HK 1190094A1 HK 14103318 A HK14103318 A HK 14103318A HK 1190094 A1 HK1190094 A1 HK 1190094A1
Authority
HK
Hong Kong
Prior art keywords
alpha
treatment
prostate cancer
integrin antibody
integrin
Prior art date
Application number
HK14103318.3A
Other languages
English (en)
Inventor
Axel Hoffmann
Heinrich Lannert
Klaus Brischwein
Frederic Christian Pipp
Juergen Reindl
Karin Groll
Michael Zuehlsdorf
Otmar Pfaff
Sabine Raab
Ulrike Dau
Benoit Destenaves
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HK1190094A1 publication Critical patent/HK1190094A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK14103318.3A 2011-02-11 2014-04-08 用於治療前列腺癌的抗-α- 整聯蛋白抗體 HK1190094A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11001135 2011-02-11
PCT/EP2012/000548 WO2012107211A1 (en) 2011-02-11 2012-02-07 Anti-alpha-v integrin antibody for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
HK1190094A1 true HK1190094A1 (zh) 2014-06-27

Family

ID=45569571

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14103318.3A HK1190094A1 (zh) 2011-02-11 2014-04-08 用於治療前列腺癌的抗-α- 整聯蛋白抗體

Country Status (24)

Country Link
US (3) US9555110B2 (zh)
EP (2) EP2672994B1 (zh)
JP (2) JP6320042B2 (zh)
KR (2) KR102103701B1 (zh)
CN (1) CN103347540B (zh)
AU (2) AU2012216145B2 (zh)
CA (1) CA2827052C (zh)
DK (1) DK2672994T3 (zh)
EA (1) EA032117B1 (zh)
ES (1) ES2683347T3 (zh)
HK (1) HK1190094A1 (zh)
HR (1) HRP20181212T1 (zh)
HU (1) HUE037212T2 (zh)
IL (1) IL227687B (zh)
LT (1) LT2672994T (zh)
MX (2) MX385144B (zh)
PL (1) PL2672994T3 (zh)
PT (1) PT2672994T (zh)
RS (1) RS57524B1 (zh)
SG (1) SG192667A1 (zh)
SI (1) SI2672994T1 (zh)
TR (1) TR201810294T4 (zh)
WO (1) WO2012107211A1 (zh)
ZA (1) ZA201306807B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2672994T (lt) 2011-02-11 2018-07-25 Merck Patent Gmbh Anti-alfa-v integrino antikūnas, skirtas prostatos vėžio gydymui
BR112017004729A2 (pt) * 2014-09-17 2017-12-05 Merck Patent Gmbh processo de tratamento de doenças causadas por metástase óssea, medicamentos para as mesmas e processo de previsão do resultado clínico de tratamento de doenças causadas por metástase óssea
SG11201702135PA (en) 2014-09-17 2017-04-27 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
SG11201804243QA (en) * 2015-11-23 2018-06-28 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
JP7034914B2 (ja) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE247168T1 (de) 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
PT719859E (pt) 1994-12-20 2003-11-28 Merck Patent Gmbh Anticorpo monoclonal anti-alfa v-integrina
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
ATE400030T1 (de) 2001-02-19 2008-07-15 Merck Patent Gmbh Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
EP2351583A1 (en) 2002-11-26 2011-08-03 Facet Biotech Corporation Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
BRPI0507608A (pt) 2004-02-12 2007-07-03 Merck Patent Gmbh formulações de anticorpos anti-egfr lìquidas altamente concentradas
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
US8202465B2 (en) 2004-11-03 2012-06-19 Honeywell International Inc. Preferential curing technique in compression molding of fiber reinforced composites
US20070025889A1 (en) 2005-07-28 2007-02-01 Pcbu Business Services, Inc. Reactors, reactor assemblies and production processes
DE102005062440B4 (de) 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
WO2008008435A2 (en) 2006-07-14 2008-01-17 Rutgers, The State University Methods, systems, and compositions for extracellular matrix production
AU2008277907B2 (en) * 2007-07-17 2013-08-22 Merck Patent Gmbh Engineered anti-alpha V- integrin hybrid antibodies
WO2009026328A2 (en) 2007-08-21 2009-02-26 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells
PT2368118E (pt) 2008-12-23 2014-01-13 Merck Patent Gmbh Biomarcadores para inibidores com atividade anti-angiogénica
CA2771441C (en) 2009-08-19 2016-10-11 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
CA2780773A1 (en) 2009-11-13 2011-05-19 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
WO2011162933A1 (en) * 2010-06-04 2011-12-29 Immunogen, Inc. Anti-integrin immunoconjugate dosing regimens
LT2672994T (lt) 2011-02-11 2018-07-25 Merck Patent Gmbh Anti-alfa-v integrino antikūnas, skirtas prostatos vėžio gydymui
JP6035716B2 (ja) 2011-08-26 2016-11-30 ソニー株式会社 情報処理システム及び情報処理方法
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

Also Published As

Publication number Publication date
US20190263913A1 (en) 2019-08-29
AU2017200998B2 (en) 2018-08-09
KR20140012087A (ko) 2014-01-29
IL227687B (en) 2019-02-28
JP6488273B2 (ja) 2019-03-20
US20170218070A1 (en) 2017-08-03
KR101972533B1 (ko) 2019-08-26
TR201810294T4 (tr) 2018-08-27
ES2683347T3 (es) 2018-09-26
ZA201306807B (en) 2014-05-28
MX352025B (es) 2017-11-07
KR20190044696A (ko) 2019-04-30
AU2017200998A1 (en) 2017-03-09
MX385144B (es) 2025-03-14
HRP20181212T1 (hr) 2018-10-05
CA2827052A1 (en) 2012-08-16
AU2012216145B2 (en) 2016-11-17
DK2672994T3 (en) 2018-07-16
JP6320042B2 (ja) 2018-05-09
SG192667A1 (en) 2013-09-30
RS57524B1 (sr) 2018-10-31
US20140086908A1 (en) 2014-03-27
LT2672994T (lt) 2018-07-25
EP3415162A1 (en) 2018-12-19
EP2672994A1 (en) 2013-12-18
US9555110B2 (en) 2017-01-31
IL227687A0 (en) 2013-09-30
CN103347540A (zh) 2013-10-09
HUE037212T2 (hu) 2018-08-28
CA2827052C (en) 2022-08-16
EA201391147A1 (ru) 2014-01-30
JP2017066156A (ja) 2017-04-06
SI2672994T1 (sl) 2018-09-28
EP2672994B1 (en) 2018-05-09
PT2672994T (pt) 2018-10-22
JP2014510047A (ja) 2014-04-24
EA032117B1 (ru) 2019-04-30
MX2013009062A (es) 2013-10-01
CN103347540B (zh) 2016-05-25
AU2012216145A1 (en) 2013-09-26
WO2012107211A1 (en) 2012-08-16
KR102103701B1 (ko) 2020-04-23
PL2672994T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
IL228738A0 (en) Antibodies for cancer treatment
PL3020730T3 (pl) Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych
IL229254A0 (en) Therapeutic antibodies
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
HK1199842A1 (zh) 抗涎免凝集素- 抗體及其用途
HRP20181212T1 (hr) Anti-alfa-v integrinsko protutijelo za liječenje raka prostate
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
TWI563004B (en) Anti-hxcr1 antibody
HK1199040A1 (zh) 抗體用途
ZA201302639B (en) Antibodies for the treatment of hiv
ZA201308992B (en) Therapeutic antibodies

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230205